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CASE

REPORT

Facklamia hominis in
hidradenitis suppurativa
Yasmeen Basal, DO,a Jerry Oommen, DO,a Usama Faraj, DO,a Robert Acho, DO,b and Amitha Aravapally, MDc
East Lansing and Clinton Township, Michigan
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition presenting with recurrent,
painful abscesses with malodorous drainage secondary to follicular occlusion of pilosebaceous units.1
Factors contributing to the development of HS
include genetic predisposition, smoking, hyperandrogenemia, and bacterial infection. The most common pathogens involved are Staphylococcus
lugdunensis and anaerobic actinomycetes1; however, here we present a rare case of HS containing
Facklamia hominis. First discovered in 1997, F.
hominis is an anaerobic bacterium infrequently
found in clinical settings. Facklamia hominis is
most often found in women, suggesting it may be
part of the normal vaginal flora; however, this
species has been found in many other sites,
including the gastrointestinal intestinal tract, bone,
and cerebrospinal fluid.2

CASE REPORT
A 64-year-old female presented to the emergency
department with a left-axillary abscess at the apex of
the axilla. Her past medical history was significant for
poorly controlled type 2 diabetes mellitus, coronary
artery disease, Hurley stage III HS (the patient did not
receive immunosuppressants due to poor compliance and follow-up), and daily tobacco use. The
abscess had been present for about 2 weeks and
worsened over the past few days. The patient denied
fevers or chills. Patient vitals during the emergency
department visit were within the normal ranges.
General surgery was consulted, and performed
bedside incision and drainage, obtained gram stain
and culture from the axillary abscess, and recommended discharge with a 7-day course of peroral
(PO) trimethoprim-sulfamethoxazole (TMP-SMX)
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Abbreviations used:
HS:
IV:
MALDI-TOF:
PO:
TMP-SMX:

hidradenitis suppurativa
intravenous
matrix-assisted laser desorption
ionizationetime-of-flight mass
spectrometry
peroral
trimethoprim-sulfamethoxazole

and outpatient follow-up. However, the patient
returned to the emergency department 5 days later
with increased pain; malodorous, brown-colored
discharge, and spread of the abscess within the
axilla. The patient’s vitals and basic lab work were
unremarkable; however, her glucose level was
elevated at 386 mg/dL. Blood cultures were also
obtained, and bedside incision and drainage was
performed. The previous wound culture demonstrated the presence of Facklamia hominis.
Susceptibility was not performed because breakpoints were not set due to the infrequent observation
of this bacterium in clinical settings. Therefore, due
to the failed trial of TMP-SMX, the patient was started
on broad-spectrum intravenous (IV) vancomycin
and piperacillin/tazobactam and admitted for further
evaluation by an infectious disease specialist. After
evaluation, antibiotic therapy was modified to IV
vancomycin and oral moxifloxacin. Over her 3-day
admission, the patient remained stable with improvements in terms of tenderness, erythema, induration, and drainage of the wound, and blood
cultures were negative. The patient was discharged
on moxifloxacin 400 mg daily and amoxicillin 1 g
every 8 hours for 7 days with outpatient infectious
disease follow-up. Although the patient showed
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Table I. Previous cases of Facklamia hominis with information on method of identification and treatment
Year

Sex

2005 F

Age

34 yrs

Source

Blood

Diagnosis

Identification

Chorioamnionitis unknown

2010 unknown unknown Blood

Endocarditis

VITEK 2 system

2012 M
2014 F

35 yrs
81 yrs

Endocarditis
Prosthetic hip
joint infection

unknown
VITEK 2 system
and confirmed
by 16S rRNA
gene
amplification

2016 F
2019 M

40 yrs
9 yrs

Blood
Periprosthetic femoral
tissue, femoral
interface
membrane,
acetabular interface
membrane
Abscess exudate
Penile exudate

2019 M

75 yrs

Urine

Treatment

Penicillin and
ampicillin
Gentamicin and
Vancomycin*
IV Ceftriaxone
6 weeks of IV
ceftriaxone
followed by
6 weeks of
ampicillin PO

Scapular abscess MALDI-TOF
Pristinamyciney
amoxicillin-clavulanic
Balanoposthitis
Mass
acid PO
spectrometry,
MALDI-TOF
Urosepsis
Gene sequencing Ampicillin-sulbactam
and vancomycin
using RAST and
Prokka with
phenotype
resistance
assessed by MIC

Reference
3

4

5
6

7
8

9

M, Male; F, female; IV, intravenous; MIC, minimal inhibitory concentration; PO, peroral; RAST, radioallergosorbent test; yrs, years old.
*Treatment was unsuccessful in eradicating bacteria.
y
Unknown if treatment was successful in eradicating bacteria.

improvement during hospital stay, no documentation of follow-up with infectious disease or surgery is
available.

DISCUSSION
To our knowledge, only 7 clinical cases involving
Facklamia hominis have been documented
(Table I).3-9 Little is known about its pathogenicity,
and there is a possibility that F. hominis could be a
contaminant in our study. However, this is less likely
due to the fact that it was the only bacterial species
grown in culture and due to the failed response to
initial TMP-SMX therapy, which would have eradicated common bacteria found in HS-associated
abscesses. As many rapid identification systems do
not include this organism in their database, multiple
methods have been used to identify F. hominis. A
2013 study found that matrix-assisted laser desorption ionizationetime-of-flight (MALDI-TOF) was
useful in identifying uncommon bacterial species.10
MALDI-TOF was used successfully to identify F.
hominis in the present case as well as in others.7,8
Although there is no standardized method of identification for F. hominis, physicians should be aware
of this method for potential use when this pathogen
is suspected.
Proper treatment of F. hominis has also proved
to be challenging for physicians. A variety of
antibiotics have been used as treatment, including

penicillins and third-generation cephalosporins
(Table I). In this case, the patient was initially given
PO TMP-SMX after incision and drainage, but it was
unsuccessful; eradication was achieved with subsequent treatment with IV vancomycin and moxifloxacin. The key discussion point here is the failure
of treatment. TMP-SMX was initiated prior to
obtaining culture results for potential methicillin
resistant Staphylococcus aureus coverage. Culture
results however demonstrated the presence of F.
hominis, which has shown responsiveness to ceftriaxone, amoxicillin, and ampicillin, but resistance
to TMP-SMX.2,3,5,6,8,9 Given the variable response to
therapy, future studies pertaining to susceptibility
are necessary in order to standardize treatment of
care and avoid antimicrobial resistance.

CONCLUSION
This is a rare case of Facklamia hominis in a
patient with HS. Although this pathogen is relatively
uncommon in clinical settings, its increasing prevalence within the past few years necessitates a need for
standardized identification and treatment. Physician
awareness in conjunction with basic science research
is vital to ensure proper care for every patient.
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